Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation-Reference-Cited by-同舟云学术

Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation

Published:2020-12 Issue:12 Volume:8 Page:973-983
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Perego Carlotta,Sbolli Marco,Specchia Claudia,Fiuzat Mona,McCaw Zachary R.,Metra Marco,Oriecuia Chiara,Peveri Giulia,Wei Lee-Jen,O’Connor Christopher M.,Psotka Mitchell A.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference42 articles.

1. Using the restricted mean survival time difference as an alternative to the hazard ratio for analyzing clinical cardiovascular studies;McCaw;Circulation,2019

2. Nonproportional hazards for time-to-event outcomes in clinical trials: JACC Review Topic of the Week;Gregson;J Am Coll Cardiol,2019

3. Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies;Uno;Ann Intern Med,2015

4. Restricted mean survival time as a measure to interpret clinical trial results;Kim;JAMA Cardiol,2017

5. Summarizing and communicating on survival data according to the audience: a tutorial on different measures illustrated with population-based cancer registry data;Belot;Clin Epidemiol,2019

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empirical adaption of Work/Rest schedules to physiological variability in heat response;Safety Science;2024-09

2. Sixteen prescribed Chinese herbal medicines provide time-dependent cardiorenal and survival benefits in patients with overall and advanced diabetic kidney disease: a real-world study in Taiwan;Frontiers in Pharmacology;2024-08-22

3. Survival loss linked to guideline-based indications for degenerative mitral regurgitation surgery;European Heart Journal - Cardiovascular Imaging;2024-07-12

4. Sentinel lymph node biopsy versus observation in high‐risk cutaneous squamous cell carcinoma in immunosuppressed and immunocompetent patients: An inverse probability of treatment weighting study;Journal of the European Academy of Dermatology and Venereology;2024-05-13

5. Summarizing Primary Results in Clinical Trials With a Time-to-Event End Point: Complementing Different Measures for a Comprehensive Assessment of Treatment Effect;Circulation;2024-04-09